Gilead Sciences (GILD) 85.07 $GILD
Uptrend Call Working As Gilead Sciences Stock Rises 17.2% (GILD)
Comtex SmarTrend(R) - Thu Jul 17, 5:28PM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 17.25% as of today's recent price of $85.07.
After Yesterday's Decline of 2.22%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 17, 4:08PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 17, 4:07PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Do Johnson & Johnson's Results Suggest a Pop or Drop for Gilead Sciences?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 17, 4:00PM CDT
Johnson & Johnson's Olysio surprised in the first quarter, as doctors increasingly turned to prescribing it alongside Gilead's Sovaldi for patients intolerant of, or unwilling to take, interferon. The fact that Olysio continued to be...
Midday Glance: Biotechnology companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Early Glance: Biotechnology companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
UnitedHealth's 2Q profit slips 2 percent
By TOM MURPHY - AP - Thu Jul 17, 10:30AM CDT
UnitedHealth Group's second-quarter earnings slipped 2 percent on a rise in taxes and other expenses, but the nation's largest health insurer still trumped analyst expectations.
The Zacks Analyst Blog Highlights:AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene
PR Newswire - Thu Jul 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Sarepta Therapeutics (Nasdaq:SRPT-Free Report) and Celgene Corp. (Nasdaq:CELG-Free Report).
The Medicines Patent Pool Signs a Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries
PR Newswire - Thu Jul 17, 3:44AM CDT
MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
Business Wire - Wed Jul 16, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the internet from the company's website.
Gilead Stock Earnings: What to Watch
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Gilead Sciences has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date. ...
Keep Calm and Carry On, J&J
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 16, 1:00PM CDT
If bellwether Johnson & Johnson is any indication, fasten your seatbelts. We're in for a volatile earnings season. The company delivered strong quarterly results, led by unexpectedly stellar sales of its new hepatitis C drug Olysio. But the...
Jim Cramer's Stop Trading: Speculation Isn't Bad
at The Street - Wed Jul 16, 10:09AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that investors have a right to speculate, despite Fed Chair Janet Yellen's thoughts on valuation.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
J&J Earnings Beat Estimates, But Guidance Mixed
at Investor's Business Daily - Tue Jul 15, 2:15PM CDT
Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue....
2 Reasons to Watch Bristol-Myers Squibb Co
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 15, 1:00PM CDT
Like many drug majors Bristol-Myers Squibb will face heavy losses to generic competition in the years ahead. In an effort to maximize efficiency the company has narrowed its focus to areas with unmet need rather than making incremental...
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Uptrend Call Working As Gilead Sciences Stock Rises 17.2% (GILD)
Comtex SmarTrend(R) - Thu Jul 17, 5:28PM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 17.25% as of today's recent price of $85.07.
After Yesterday's Decline of 2.22%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 17, 4:08PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 17, 4:07PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Do Johnson & Johnson's Results Suggest a Pop or Drop for Gilead Sciences?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 17, 4:00PM CDT
Johnson & Johnson's Olysio surprised in the first quarter, as doctors increasingly turned to prescribing it alongside Gilead's Sovaldi for patients intolerant of, or unwilling to take, interferon. The fact that Olysio continued to be...
Midday Glance: Biotechnology companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Early Glance: Biotechnology companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
UnitedHealth's 2Q profit slips 2 percent
By TOM MURPHY - AP - Thu Jul 17, 10:30AM CDT
UnitedHealth Group's second-quarter earnings slipped 2 percent on a rise in taxes and other expenses, but the nation's largest health insurer still trumped analyst expectations.
The Zacks Analyst Blog Highlights:AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene
PR Newswire - Thu Jul 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Sarepta Therapeutics (Nasdaq:SRPT-Free Report) and Celgene Corp. (Nasdaq:CELG-Free Report).
The Medicines Patent Pool Signs a Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries
PR Newswire - Thu Jul 17, 3:44AM CDT
MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
Business Wire - Wed Jul 16, 4:00PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the internet from the company's website.
Gilead Stock Earnings: What to Watch
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Gilead Sciences has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date. ...
Keep Calm and Carry On, J&J
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 16, 1:00PM CDT
If bellwether Johnson & Johnson is any indication, fasten your seatbelts. We're in for a volatile earnings season. The company delivered strong quarterly results, led by unexpectedly stellar sales of its new hepatitis C drug Olysio. But the...
Jim Cramer's Stop Trading: Speculation Isn't Bad
at The Street - Wed Jul 16, 10:09AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued that investors have a right to speculate, despite Fed Chair Janet Yellen's thoughts on valuation.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
J&J Earnings Beat Estimates, But Guidance Mixed
at Investor's Business Daily - Tue Jul 15, 2:15PM CDT
Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue....
2 Reasons to Watch Bristol-Myers Squibb Co
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 15, 1:00PM CDT
Like many drug majors Bristol-Myers Squibb will face heavy losses to generic competition in the years ahead. In an effort to maximize efficiency the company has narrowed its focus to areas with unmet need rather than making incremental...
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
